Archive | October, 2012

Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More

Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with the overall sector up 40%. Despite recent media coverage of […]

Continue Reading 0

Cepheid (CPHD $31.40)-Good Entry Point For Long Term

Cepheid in Low $30’s- Long Term Buy Cepheid is not a cheap stock with a Price to Sales of 6.82, market cap of $2.10B and a forward PE of 122.58 but we see a capitulation of sellers who were playing the MO game with a very expensive stock. Nonetheless Cepheid is a high quality Company […]

Continue Reading 0

NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24

Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and  Gilead (GILD $68.85) up 6%. Biogen Idec earnings are due tomorrow. See summary below of 2012 […]

Continue Reading 0

Rayno Life Sciences: Investor Election Guide from Credit Suisse

Ultimate Presidential Election Guide Click above for an interesting sector and stock review from Credit Suisse including major positions of candidates. Stocks in the Rayno Life Sciences Portfolio that were mentioned on the “Obama Victory” side include: Illumina (ILMN) and ThermoFisher (TMO) On the “Romney Victory” side include many medTech stocks such as Baxter (BAX) […]

Continue Reading 0

Will The Biotechnology Bull Market Stimulate Venture Investing?

Notes from the BioInvestor Forum October 9-12–Biotech Investing The BioInvestor Forum held every year at this time in San Francisco is one of the premier events for emerging companies. Over 500 investors and companies attended with 7 major sessions on investing and innovation trends. Over 100 private and public companies made a 20 minute presentation. […]

Continue Reading 0

Rayno Life Science DX and Tools Update: EXAS

Exact Sciences (EXAS) is down about 8% to $10.65 on heavy volume after a Wedbush Downgrade to Neutral. Preliminary data coming next week. The stock was added to the Rayno Life Sciences Portfolio on 12/10/10.Barron’s had a positive article on Oct 6 and the Company raised $58M in August with a follow-on offering. The stock […]

Continue Reading 0

Rayno Life Science Portfolios: Biotechnology Stocks Should Outperform in Q4

Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The Company is developing clinical stage therapeutics to treat chronic liver diseases. BofA MerrillLynch is acting as sole book running manager with […]

Continue Reading 0

Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN

Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks […]

Continue Reading 0

Rayno Life Science Portfolio Dx and Tools: EXAS, ILMN,TMO

Molecular Plays Lead Rayno Dx Focus Stocks Up Illumina (ILMN) rose 4.5% today on “talk” that Roche will increase its buyout offer to $60. Roche told Bloomberg that it does not comment on rumors. Illumina was added to the Rayno Portfolio in 2/2/09 at a price of $29 and the buy was reiterated in 2012 in […]

Continue Reading 0